EuroPCR 2024: Late-Breaking Science Video Collection
Published: 20 May 2024
-
Views:
1043
-
Likes:
7
-
Views:
1043
-
Likes:
7
-
Up Next -
3m 59sPart 1 | Session 4 Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY -
4m 6s -
26m 48sPart 1 | Session 6 1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II
-
26m 3sPart 2 | Session 1 View from the Thoraxcenter: What's Hot at EuroPCR 24? -
18m 29sPart 2 | Session 2 View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1
-
4m 13sPart 3 | Session 1 5 Trials That Will Change My Practice With Dr Mirvat Alasnag -
6m 27sPart 3 | Session 2 4 Trials That Will Change My Practice with Dr Bernardo Cortese
-
4m 31sPart 1 | Session 1 Self-Expandable Vs Balloon-Expandable Valves & General Vs Local Anesthesia in TAVI: SOLVE-TAVI Hans-Josef Feistritzer
-
3m 44sPart 1 | Session 2 Influence of Pathophysiological Patterns of CAD on PCI Carlos Collet
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.
More from this programme
Part 1
Expert Interviews
Part 2
View from the Thoraxcenter
Part 3
Highlights Reviews
About the episode
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) joins us to discuss the findings from an ancillary analysis of the SMART trial (NCT04722250).
The SMART trial is a prospective, multi-center, randomized controlled study that aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli and severe symptomatic aortic stenosis. At select sites, a stress echocardiography sub-study also evaluated the performance of self expandable and balloon-expandable TAVR in this patient group, after exercise stress testing.
716 patients were enrolled in the trial, and were randomized on a 1:1 basis to receive TAVR with either a Medtronic self-expanding transcatheter aortic valve, or an Edwards balloon-expandable transcatheter heart valve.
Interview Questions:
- What is the reasoning behind this ancillary study?
- Could you tell us about the patient groups and data that were studied?
- What were your key findings?
- What is the implication of these findings on clinical practice?
- In short, what is your take-home message for clinicians?
- Where are the remaining knowledge gaps?
Recorded on-site at EuroPCR Congress, Paris, 2024.
Editor: Jordan Rance
Video Specialists: Dan Brent,
Interviewer: Liam O'Neill
Faculty Biographies
Roxana Mehran
Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Roxana Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.
Roxana serves on editorial board of multiple peer reviewed journals, including …
Comments